"Talk about tumor immunity and help precision medicine", on August 12-13, the 8th Global Precision Medicine (China) Summit and the 4th Cancer Immunotherapy Leadership Summit were held
.
The domestic immune cell market is poised for development and full of
momentum.
In addition to policy support, with the popularization of knowledge related to immune cell therapy, the market has paid more attention to this field, providing room
for the industry to develop.
Immune cells iterate fast NK cells into the development sequence
Research on tumor immune cells has developed rapidly, and the relevant research on CAR-T therapy, the most concerned of which has been iteratively updated, has enhanced the specificity and targeting of anti-tumor, while the killing activity and persistence have also been enhanced
.
In addition to CAR-T therapy, other cellular immunotherapy research has also begun to advance and achieve remarkable results
.
The study, published in the December 2019 issue of Precision Clinical Medicine, explored the effectiveness of natural killer (NK) cell immunotherapy for non-small cell lung cancer with or without EGFR mutations to assess response rates (RRs) and progression-free survival (PFS).
In addition, the latest research conducted by the team of Professor Jiang Yong of the Guangdong Provincial Key Laboratory of Proteomics shows that PD-1 inhibitors have an effect on non-small cell lung cancer in clinical treatment, and found that in addition to T cells, NK cells are not only able to express PD-1 proteins, but also have the potential
to prolong the survival of patients with advanced non-small cell lung cancer.
Academic research results on immunotherapy based on natural killer (NK) cells are emerging in an endless stream, and related clinical technologies and products are also expected to be born and produce results
.
Zhongying Bio showcases NK cell clinical technology achievements and leading the industry in advantageous technology
Zhongying Bio's drug standard grade NK/CAR-NK cell amplification reagent will be displayed during the conference, Zhongying Bio has independent intellectual property rights based on IL21 trophoblast cell preparation NK cell method relative to other ways to be stable, the prepared final product effector cells can basically reach more than 90% purity, and the expansion multiple is high, the killing function is strong
.
The relevant person in charge of Zhongying Bio made a professional interpretation
of the in vitro preparation method of IL21 at the meeting.
It is understood that IL-21 transmembrane NK cell in vitro directional expansion activation technology, belongs to the fourth generation of NK cell amplification technology
.
In 2021, this product of Zhongying Bio passed the three safety evaluations of in vitro tumorigenesis, in vivo tumor formation and tumorigenicity of the National New Drug Shanghai Safety Evaluation Center in accordance with the drug regulatory standards of China, the United States and Europe, providing a safety certificate
for Zhongying Bio's patented products on NK cells.
In addition to the fourth generation of IL21 amplification NK cell technology, Zhongying Bio has a number of core technologies that have obtained national invention patents and have many technical reserves: such as the development and improvement of NK cell amplification kit, cytokine NK cell amplification technology, etc
.
In addition to NK cells, Zhongying Bio also has the technology to efficiently expand other immune cells, such as NKT cells, T cells, etc.
"Talk about tumor immunity and help precision medicine", on August 12-13, the 8th Global Precision Medicine (China) Summit and the 4th Cancer Immunotherapy Leadership Summit were held
.
The domestic immune cell market is poised for development and full of
momentum.
In addition to policy support, with the popularization of knowledge related to immune cell therapy, the market has paid more attention to this field, providing room
for the industry to develop.
Immune cells iterate fast NK cells into the development sequence
Research on tumor immune cells has developed rapidly, and the relevant research on CAR-T therapy, the most concerned of which has been iteratively updated, has enhanced the specificity and targeting of anti-tumor, while the killing activity and persistence have also been enhanced
.
In addition to CAR-T therapy, other cellular immunotherapy research has also begun to advance and achieve remarkable results
.
For example, NK cells have been shown to be a promising treatment method for solid tumors and hematologic malignancies: according to medical research, NK cells do not need the pre-stimulation of tumor antigens, they can find and activate immune defense functions at the first time, directly kill tumor cells, and at the same time induce apoptosis by releasing cytokines, which is recognized by the medical community as the first line of defense
against cancer.
The study, published in the December 2019 issue of Precision Clinical Medicine, explored the effectiveness of natural killer (NK) cell immunotherapy for non-small cell lung cancer with or without EGFR mutations to assess response rates (RRs) and progression-free survival (PFS).
In addition, the latest research conducted by the team of Professor Jiang Yong of the Guangdong Provincial Key Laboratory of Proteomics shows that PD-1 inhibitors have an effect on non-small cell lung cancer in clinical treatment, and found that in addition to T cells, NK cells are not only able to express PD-1 proteins, but also have the potential
to prolong the survival of patients with advanced non-small cell lung cancer.
Academic research results on immunotherapy based on natural killer (NK) cells are emerging in an endless stream, and related clinical technologies and products are also expected to be born and produce results
.
Zhongying Bio showcases NK cell clinical technology achievements and leading the industry in advantageous technology
Zhongying Bio's drug standard grade NK/CAR-NK cell amplification reagent will be displayed during the conference, Zhongying Bio has independent intellectual property rights based on IL21 trophoblast cell preparation NK cell method relative to other ways to be stable, the prepared final product effector cells can basically reach more than 90% purity, and the expansion multiple is high, the killing function is strong
.
The relevant person in charge of Zhongying Bio made a professional interpretation
of the in vitro preparation method of IL21 at the meeting.
It is understood that IL-21 transmembrane NK cell in vitro directional expansion activation technology, belongs to the fourth generation of NK cell amplification technology
.
NK cells amplified by winning amplification system can be expanded to more than 10,000 times in a short period of time, the purity reaches more than 90%, the killing rate is increased to more than 85%, and the telomerase activity of NK cells is not reduced, and there is no premature aging
.
In 2021, this product of Zhongying Bio passed the three safety evaluations of in vitro tumorigenesis, in vivo tumor formation and tumorigenicity of the National New Drug Shanghai Safety Evaluation Center in accordance with the drug regulatory standards of China, the United States and Europe, providing a safety certificate
for Zhongying Bio's patented products on NK cells.
In addition to the fourth generation of IL21 amplification NK cell technology, Zhongying Bio has a number of core technologies that have obtained national invention patents and have many technical reserves: such as the development and improvement of NK cell amplification kit, cytokine NK cell amplification technology, etc
.
In addition to NK cells, Zhongying Bio also has the technology to efficiently expand other immune cells, such as NKT cells, T cells, etc.
, and also has the purification and preparation technology
of health care products such as goji polysaccharide chewable tablets.
In addition, Zhongying Bio is also developing iPS-NK cell preparation technology
.
"Talk about tumor immunity and help precision medicine", on August 12-13, the 8th Global Precision Medicine (China) Summit and the 4th Cancer Immunotherapy Leadership Summit were held
.
Zhongying Bio was invited to participate in the conference and gave a keynote speech
on "In vitro preparation method of IL21 (trophoblasts)-based NK/CAR-NK cells".
The domestic immune cell market is poised for development and full of
momentum.
In particular, the relevant policy orientation presents a two-way promotion of "encouragement" and "standardization", which makes the development of cell therapy, including immune cell therapy, enter the fast lane
.
In addition to policy support, with the popularization of knowledge related to immune cell therapy, the market has paid more attention to this field, providing room
for the industry to develop.
Immune cells iterate fast NK cells into the development sequence
Immune cells iterate fast NK cells into the development sequence
Research on tumor immune cells has developed rapidly, and the relevant research on CAR-T therapy, the most concerned of which has been iteratively updated, has enhanced the specificity and targeting of anti-tumor, while the killing activity and persistence have also been enhanced
.
In addition to CAR-T therapy, other cellular immunotherapy research has also begun to advance and achieve remarkable results
.
For example, NK cells have been shown to be a promising treatment method for solid tumors and hematologic malignancies: according to medical research, NK cells do not need the pre-stimulation of tumor antigens, they can find and activate immune defense functions at the first time, directly kill tumor cells, and at the same time induce apoptosis by releasing cytokines, which is recognized by the medical community as the first line of defense
against cancer.
The study, published in the December 2019 issue of Precision Clinical Medicine, explored the effectiveness of natural killer (NK) cell immunotherapy for non-small cell lung cancer with or without EGFR mutations to assess response rates (RRs) and progression-free survival (PFS).
In addition, the latest research conducted by the team of Professor Jiang Yong of the Guangdong Provincial Key Laboratory of Proteomics shows that PD-1 inhibitors have an effect on non-small cell lung cancer in clinical treatment, and found that in addition to T cells, NK cells are not only able to express PD-1 proteins, but also have the potential
to prolong the survival of patients with advanced non-small cell lung cancer.
Academic research results on immunotherapy based on natural killer (NK) cells are emerging in an endless stream, and related clinical technologies and products are also expected to be born and produce results
.
Zhongying Bio showcases NK cell clinical technology achievements and leading the industry in advantageous technology
Zhongying Bio showcases NK cell clinical technology achievements and leading the industry in advantageous technology
Zhongying Bio's drug standard grade NK/CAR-NK cell amplification reagent will be displayed during the conference, Zhongying Bio has independent intellectual property rights based on IL21 trophoblast cell preparation NK cell method relative to other ways to be stable, the prepared final product effector cells can basically reach more than 90% purity, and the expansion multiple is high, the killing function is strong
.
The relevant person in charge of Zhongying Bio made a professional interpretation
of the in vitro preparation method of IL21 at the meeting.
It is understood that IL-21 transmembrane NK cell in vitro directional expansion activation technology, belongs to the fourth generation of NK cell amplification technology
.
NK cells amplified by winning amplification system can be expanded to more than 10,000 times in a short period of time, the purity reaches more than 90%, the killing rate is increased to more than 85%, and the telomerase activity of NK cells is not reduced, and there is no premature aging
.
In 2021, this product of Zhongying Bio passed the three safety evaluations of in vitro tumorigenesis, in vivo tumor formation and tumorigenicity of the National New Drug Shanghai Safety Evaluation Center in accordance with the drug regulatory standards of China, the United States and Europe, providing a safety certificate
for Zhongying Bio's patented products on NK cells.
In addition to the fourth generation of IL21 amplification NK cell technology, Zhongying Bio has a number of core technologies that have obtained national invention patents and have many technical reserves: such as the development and improvement of NK cell amplification kit, cytokine NK cell amplification technology, etc
.
In addition to NK cells, Zhongying Bio also has the technology to efficiently expand other immune cells, such as NKT cells, T cells, etc.
, and also has the purification and preparation technology
of health care products such as goji polysaccharide chewable tablets.
In addition, Zhongying Bio is also developing iPS-NK cell preparation technology
.
